Opinion
Video
Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC
Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.
EP: 1.Hepatocellular Carcinoma (HCC) Disease State Overview
EP: 2.Utilizing Interventional Radiology and Liver-directed Therapies
Now Viewing
EP: 3.Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC
EP: 4.EMERALD-1 Study: Significance as Presented at ASCO GI 2024
EP: 5.EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies
EP: 6.IMBrave-050 Study Overview
EP: 7.Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab
EP: 8.HIMALAYA Study in Advanced Stage HCC
EP: 9.Establishing Optimal HCC Treatment Strategy
EP: 10.IMBrave150 Study Overview
EP: 11.HCC Treatment Strategy Driven by Real-World Evidence
EP: 12.Combining Liver-directed and Systemic Therapies in HCC
EP: 13.Patient Profile 2: Patient Progression After Frontline HCC Therapy
EP: 14.CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape
EP: 15.REGONEXT Study: Driving Second-line HCC Treatment Strategy
EP: 16.Trajectory of Evolving HCC Treatment Landscape
Related Videos
Related Content
Published: July 19th 2024 | Updated: July 19th 2024
EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC
